Renal late effects in patients treated for cancer in childhood: A report from the Children's Oncology Group
Improvements in childhood cancer therapy have led to increasing numbers of long‐term survivors. These survivors are at risk for a variety of late effects due to the disease itself, treatment exposures (surgery, chemotherapy, and radiotherapy), underlying medical problems, and health behaviors. The C...
Saved in:
| Published in: | Pediatric blood & cancer Vol. 51; no. 6; pp. 724 - 731 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01-12-2008
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Improvements in childhood cancer therapy have led to increasing numbers of long‐term survivors. These survivors are at risk for a variety of late effects due to the disease itself, treatment exposures (surgery, chemotherapy, and radiotherapy), underlying medical problems, and health behaviors. The COG LTFU Guidelines are risk‐based, exposure‐related recommendations for the identification and management of late effects due to therapies utilized in the treatment of childhood cancer, and are designed for asymptomatic survivors presenting for routine medical follow‐up 2 or more years after completion of cancer therapy. The COG Guidelines Task Force on Urinary Tract Complications conducted an extensive review of the medical literature via MEDLINE. Specific treatment exposures which were reviewed include nephrectomy, chemotherapy regimens known to be nephrotoxic (cisplatin, carboplatin, ifosfamide, and methotrexate), and renal irradiation. Literature sources were ranked according to the strength of evidence and are cited in the review. This review summarizes the literature that supported the recommendations for cancer survivors at risk for nephrotoxicity previously outlined in the Children's Oncology Group Long‐Term Follow‐Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancers (COG LTFU Guidelines). Pediatr Blood Cancer 2008;51:724–731. © 2008 Wiley‐Liss, Inc. |
|---|---|
| AbstractList | Improvements in childhood cancer therapy have led to increasing numbers of long-term survivors. These survivors are at risk for a variety of late effects due to the disease itself, treatment exposures (surgery, chemotherapy, and radiotherapy), underlying medical problems, and health behaviors. The COG LTFU Guidelines are risk-based, exposure-related recommendations for the identification and management of late effects due to therapies utilized in the treatment of childhood cancer, and are designed for asymptomatic survivors presenting for routine medical follow-up 2 or more years after completion of cancer therapy. The COG Guidelines Task Force on Urinary Tract Complications conducted an extensive review of the medical literature via MEDLINE. Specific treatment exposures which were reviewed include nephrectomy, chemotherapy regimens known to be nephrotoxic (cisplatin, carboplatin, ifosfamide, and methotrexate), and renal irradiation. Literature sources were ranked according to the strength of evidence and are cited in the review. This review summarizes the literature that supported the recommendations for cancer survivors at risk for nephrotoxicity previously outlined in the Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancers (COG LTFU Guidelines). Improvements in childhood cancer therapy have led to increasing numbers of long‐term survivors. These survivors are at risk for a variety of late effects due to the disease itself, treatment exposures (surgery, chemotherapy, and radiotherapy), underlying medical problems, and health behaviors. The COG LTFU Guidelines are risk‐based, exposure‐related recommendations for the identification and management of late effects due to therapies utilized in the treatment of childhood cancer, and are designed for asymptomatic survivors presenting for routine medical follow‐up 2 or more years after completion of cancer therapy. The COG Guidelines Task Force on Urinary Tract Complications conducted an extensive review of the medical literature via MEDLINE. Specific treatment exposures which were reviewed include nephrectomy, chemotherapy regimens known to be nephrotoxic (cisplatin, carboplatin, ifosfamide, and methotrexate), and renal irradiation. Literature sources were ranked according to the strength of evidence and are cited in the review. This review summarizes the literature that supported the recommendations for cancer survivors at risk for nephrotoxicity previously outlined in the Children's Oncology Group Long‐Term Follow‐Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancers ( COG LTFU Guidelines ). Pediatr Blood Cancer 2008;51:724–731. © 2008 Wiley‐Liss, Inc. Improvements in childhood cancer therapy have led to increasing numbers of long‐term survivors. These survivors are at risk for a variety of late effects due to the disease itself, treatment exposures (surgery, chemotherapy, and radiotherapy), underlying medical problems, and health behaviors. The COG LTFU Guidelines are risk‐based, exposure‐related recommendations for the identification and management of late effects due to therapies utilized in the treatment of childhood cancer, and are designed for asymptomatic survivors presenting for routine medical follow‐up 2 or more years after completion of cancer therapy. The COG Guidelines Task Force on Urinary Tract Complications conducted an extensive review of the medical literature via MEDLINE. Specific treatment exposures which were reviewed include nephrectomy, chemotherapy regimens known to be nephrotoxic (cisplatin, carboplatin, ifosfamide, and methotrexate), and renal irradiation. Literature sources were ranked according to the strength of evidence and are cited in the review. This review summarizes the literature that supported the recommendations for cancer survivors at risk for nephrotoxicity previously outlined in the Children's Oncology Group Long‐Term Follow‐Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancers (COG LTFU Guidelines). Pediatr Blood Cancer 2008;51:724–731. © 2008 Wiley‐Liss, Inc. |
| Author | Jones, Deborah P. Green, Daniel Spunt, Sheri L. Springate, James E. |
| Author_xml | – sequence: 1 givenname: Deborah P. surname: Jones fullname: Jones, Deborah P. email: dpjones@utmem.edu organization: University of Tennessee Health Science Center, Children's Foundation Research Center at Le Bonheur Children's Medical Center, Memphis, Tennessee – sequence: 2 givenname: Sheri L. surname: Spunt fullname: Spunt, Sheri L. organization: Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee – sequence: 3 givenname: Daniel surname: Green fullname: Green, Daniel organization: Department of Epidemiology and Cancer Prevention, St. Jude Children's Research Hospital, Memphis, Tennessee – sequence: 4 givenname: James E. surname: Springate fullname: Springate, James E. organization: Department of Pediatrics, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, New York |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/18677764$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kEtPwzAQhC0E4n3gDyDfEIeA7dhxzAGpFChICBAC9Wi5zpoGUjtywqP_npRCgQOnXWm-mdXOBlr2wQNCO5QcUELYYT2yB4xmSiyhdSq4SAShcnmxE7WGNprmqUMzIvJVtEbzTEqZ8XX0fAfeVLgyLWBwDmzb4NLj2rQl-G5vI3RSgV2I2BpvIc5kOy6rYhxCcYR7OEIdYotdDBPcjgH3Z2IEv9fgG29DFR6neBDDS72FVpypGtj-mpvo4fzsvn-RXN0MLvu9q8QKKkXCHFBV5BxkmqUUTDFyShUq5yoXlqecqMIpxxhPJZMcrGLSAQOSKyCOZjzdRMfz3PplNIHCdo9EU-k6lhMTpzqYUv9VfDnWj-FVM5lyQVUXsD8PsDE0TQS38FKiZ43rrnH92XjH7v4-9kN-VdwBh3Pgraxg-n-Svj3pf0cmc0fZtPC-cJj4rDOZSqGH1wM9HN6dqovzob5OPwBYAp09 |
| CitedBy_id | crossref_primary_10_1002_pbc_26538 crossref_primary_10_1002_1878_0261_12044 crossref_primary_10_3727_096504017X14992942781895 crossref_primary_10_1007_s00467_010_1653_4 crossref_primary_10_1007_s13730_014_0124_3 crossref_primary_10_1016_j_ejca_2021_06_050 crossref_primary_10_3390_ijms232113093 crossref_primary_10_1161_CIR_0b013e3182a88099 crossref_primary_10_1007_s00280_015_2913_6 crossref_primary_10_3390_cancers16091634 crossref_primary_10_13005_bpj_1791 crossref_primary_10_1016_j_taap_2013_08_012 crossref_primary_10_1097_CAD_0b013e3283650bda crossref_primary_10_1007_s00467_017_3765_6 crossref_primary_10_1016_j_ppedcard_2015_10_001 crossref_primary_10_1007_s00467_018_3976_5 crossref_primary_10_1200_JCO_22_01926 crossref_primary_10_1007_s00467_019_04397_2 crossref_primary_10_1080_08880018_2018_1476941 crossref_primary_10_1016_j_yapd_2017_04_001 crossref_primary_10_1002_pbc_25897 crossref_primary_10_1200_JCO_2015_62_7562 crossref_primary_10_1002_pbc_22344 crossref_primary_10_1016_j_ijrobp_2012_05_024 crossref_primary_10_1038_nrc3634 crossref_primary_10_3165_jjpn_oa_2018_0143 crossref_primary_10_1002_ijc_32687 crossref_primary_10_1016_j_paed_2013_06_003 crossref_primary_10_1002_14651858_CD008944_pub3 crossref_primary_10_1007_s11845_016_1473_z crossref_primary_10_3390_jcm10030399 crossref_primary_10_1002_14651858_CD008944_pub2 crossref_primary_10_1016_j_redox_2018_09_020 crossref_primary_10_1126_scitranslmed_aba5942 crossref_primary_10_18632_oncotarget_23256 crossref_primary_10_1111_bcp_12554 crossref_primary_10_1016_j_urology_2012_10_016 crossref_primary_10_3390_curroncol29080421 crossref_primary_10_1007_s00280_020_04164_3 crossref_primary_10_1007_s11764_012_0241_y crossref_primary_10_1016_j_urolonc_2012_08_002 crossref_primary_10_1097_MOP_0000000000000681 crossref_primary_10_1002_pbc_26132 crossref_primary_10_1002_pbc_29567 crossref_primary_10_1016_j_ajpath_2011_08_006 crossref_primary_10_1177_1078155220961550 crossref_primary_10_1007_s11060_013_1203_6 crossref_primary_10_1097_COC_0000000000001123 crossref_primary_10_1097_MD_0000000000014921 crossref_primary_10_1080_10245332_2016_1259713 crossref_primary_10_4155_fsoa_2018_0045 crossref_primary_10_1111_ped_12542 crossref_primary_10_1007_s00112_008_1861_1 crossref_primary_10_1097_CCO_0b013e328329f201 crossref_primary_10_1188_18_CJON_175_183 crossref_primary_10_1016_j_ejca_2022_05_038 crossref_primary_10_1007_s40141_023_00409_3 crossref_primary_10_2217_phe_10_60 crossref_primary_10_1016_j_bulcan_2015_03_016 crossref_primary_10_1200_JCO_22_02111 crossref_primary_10_3389_fonc_2021_804685 crossref_primary_10_1016_j_ctrv_2018_05_001 crossref_primary_10_2215_CJN_09980912 crossref_primary_10_1590_s1677_5538_ibju_2018_0126 crossref_primary_10_1016_j_yapd_2017_03_014 crossref_primary_10_1016_j_blre_2019_03_003 crossref_primary_10_3109_10408444_2011_602662 crossref_primary_10_1016_j_urolonc_2015_06_008 crossref_primary_10_1016_j_pop_2009_07_007 crossref_primary_10_1016_j_semnephrol_2010_09_005 crossref_primary_10_1053_j_ackd_2021_09_001 crossref_primary_10_1007_s00467_022_05632_z crossref_primary_10_1016_j_jpeds_2018_12_023 crossref_primary_10_4103_AJPN_AJPN_29_20 crossref_primary_10_1093_jjco_hyt132 crossref_primary_10_1158_1055_9965_EPI_13_0036 crossref_primary_10_1097_MPH_0b013e318257fd89 crossref_primary_10_1016_j_bbmt_2016_01_023 crossref_primary_10_1016_j_amjmed_2012_01_013 crossref_primary_10_1016_j_ejca_2016_05_006 crossref_primary_10_1590_S1679_45082015RW3102 crossref_primary_10_1002_pbc_24572 crossref_primary_10_1097_MD_0000000000001413 crossref_primary_10_1111_iju_12017 crossref_primary_10_1016_j_bulcan_2022_11_009 crossref_primary_10_1002_cncr_32063 crossref_primary_10_1053_j_seminoncol_2013_09_009 crossref_primary_10_1158_1055_9965_EPI_22_0925 |
| Cites_doi | 10.1159/000227539 10.1097/00000421-199306000-00003 10.1038/sj.bjc.6600608 10.1097/01.ASN.0000042803.28024.92 10.1097/00008480-199504000-00016 10.1002/pbc.20228 10.1002/cncr.20255 10.1016/S0022-3476(05)80557-8 10.1002/(SICI)1096-911X(199701)28:1<35::AID-MPO7>3.0.CO;2-U 10.1016/S0022-5347(05)64420-5 10.1097/01.ju.0000176800.00994.3a 10.1001/archinte.146.4.705 10.1542/peds.44.6.912 10.1038/bjc.1998.276 10.1177/009127009903900504 10.1007/s003830050482 10.1002/1097-0142(19951215)76:12<2557::AID-CNCR2820761223>3.0.CO;2-9 10.1007/BF00860940 10.1097/01.ju.0000084430.96658.05 10.1097/01.ju.0000083999.16060.ff 10.1097/00000421-199802000-00013 10.1007/s004670050585 10.1002/pbc.10480 10.1002/mpo.10336 10.1111/j.1651-2227.1986.tb10222.x 10.1016/S0022-3476(85)80098-6 10.1136/adc.67.12.1462 10.1542/peds.101.6.e8 10.1016/S0022-3476(05)83372-4 10.1002/pbc.20858 10.1002/mpo.10293 10.1016/S0360-3016(99)00534-9 10.1016/S0022-5347(05)64219-X 10.1002/(SICI)1096-911X(199602)26:2<75::AID-MPO1>3.0.CO;2-R 10.1002/(SICI)1096-911X(199903)32:3<177::AID-MPO3>3.0.CO;2-H 10.1016/0959-8049(95)00618-4 10.1097/00043426-200003000-00007 10.1016/S0022-3476(86)80781-8 10.1200/JCO.1991.9.12.2177 10.1016/S0270-9295(03)00093-7 10.1007/s002280100319 10.1002/(SICI)1096-911X(199902)32:2<93::AID-MPO4>3.0.CO;2-Y 10.1542/peds.107.5.1205 10.1038/bjc.1992.378 10.1002/(SICI)1096-911X(199609)27:3<149::AID-MPO3>3.0.CO;2-E 10.1016/j.admecli.2004.09.012 |
| ContentType | Journal Article |
| Copyright | Copyright © 2008 Wiley‐Liss, Inc. |
| Copyright_xml | – notice: Copyright © 2008 Wiley‐Liss, Inc. |
| CorporateAuthor | Children's Oncology Group |
| CorporateAuthor_xml | – name: Children's Oncology Group |
| DBID | BSCLL CGR CUY CVF ECM EIF NPM AAYXX CITATION 5PM |
| DOI | 10.1002/pbc.21695 |
| DatabaseName | Istex Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef PubMed Central (Full Participant titles) |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
| DatabaseTitleList | MEDLINE CrossRef |
| Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1545-5017 |
| EndPage | 731 |
| ExternalDocumentID | 10_1002_pbc_21695 18677764 PBC21695 ark_67375_WNG_WWRD9HFW_N |
| Genre | reviewArticle Journal Article Review |
| GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: K23 HL083910-01A2 |
| GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 123 1L6 1OC 31~ 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5VS 66C 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAWTL AAXRX AAZKR ABCQN ABCUV ABEML ABIJN ABPPZ ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EJD EMOBN F00 F01 F04 F5P FEDTE FUBAC G-S G.N GNP GODZA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 QRW R.K ROL RWI RX1 RYL SUPJJ SV3 TEORI UB1 UDS V2E W8V W99 WBKPD WHWMO WIH WIJ WIK WJL WOHZO WQJ WRC WVDHM WXI WXSBR XG1 XV2 ~IA ~WT CGR CUY CVF ECM EIF NPM AAMNL AAYXX CITATION 5PM |
| ID | FETCH-LOGICAL-c5175-2fe19d84e73631eadbf99d984985c43409df9f22437274ec927fe2e089e0f1643 |
| IEDL.DBID | 33P |
| ISSN | 1545-5009 |
| IngestDate | Tue Sep 17 21:14:22 EDT 2024 Fri Nov 22 00:27:06 EST 2024 Sat Sep 28 07:49:34 EDT 2024 Sat Aug 24 00:57:41 EDT 2024 Wed Oct 30 09:50:29 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5175-2fe19d84e73631eadbf99d984985c43409df9f22437274ec927fe2e089e0f1643 |
| Notes | ark:/67375/WNG-WWRD9HFW-N istex:6191DFAC8FB2700A7DEB60EEA906296A8008FD4C ArticleID:PBC21695 Professor of Pediatrics. Member. Associate Member. Associate Professor. |
| OpenAccessLink | https://europepmc.org/articles/pmc2734519?pdf=render |
| PMID | 18677764 |
| PageCount | 8 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_2734519 crossref_primary_10_1002_pbc_21695 pubmed_primary_18677764 wiley_primary_10_1002_pbc_21695_PBC21695 istex_primary_ark_67375_WNG_WWRD9HFW_N |
| PublicationCentury | 2000 |
| PublicationDate | December 2008 |
| PublicationDateYYYYMMDD | 2008-12-01 |
| PublicationDate_xml | – month: 12 year: 2008 text: December 2008 |
| PublicationDecade | 2000 |
| PublicationPlace | Hoboken |
| PublicationPlace_xml | – name: Hoboken – name: United States |
| PublicationTitle | Pediatric blood & cancer |
| PublicationTitleAlternate | Pediatr. Blood Cancer |
| PublicationYear | 2008 |
| Publisher | Wiley Subscription Services, Inc., A Wiley Company |
| Publisher_xml | – name: Wiley Subscription Services, Inc., A Wiley Company |
| References | Burk CD, Restaino I, Kaplan BS, et al. Ifosfamide-induced renal tubular dysfunction and rickets in children with Wilms tumor. J Pediatr 1990; 117: 331-335. Wikstad I, Pettersson BA, Elinder G, et al. A comparative study of size and function of the remnant kidney in patients nephrectomized in childhood for Wilms' tumor and hydronephrosis. Acta Paediatr Scand 1986; 75: 408-414. Wan J, Corvino TF, Greenfield SP, et al. The incidence of recreational genitourinary and abdominal injuries in the Western New York pediatric population. J Urol 2003; 170: 1525-1527; discussion 1527. Schell M, Cochat P, Hadj-Aissa A, et al. Renal function following unilateral nephrectomy for neuroblastoma and Wilms' tumour. Pediatr Nephrol 1995; 9: 579-582. Mitus A, Tefft M, Fellers FX. Long-term follow-up of renal functions of 108 children who underwent nephrectomy for malignant disease. Pediatrics 1969; 44: 912-921. Finklestein JZ, Norkool P, Green DM, et al. Diastolic hypertension in Wilms' tumor survivors: A late effect of treatment? A report from the National Wilms' Tumor Study Group. Am J Clin Oncol 1993; 16: 201-205. Breslow NE, Collins AJ, Ritchey ML, et al. End stage renal disease in patients with Wilms tumor: Results from the National Wilms Tumor Study Group and the United States Renal Data System. J Urol 2005; 174: 1972-1975. Brock PR, Koliouskas DE, Barratt TM, et al. Partial reversibility of cisplatin nephrotoxicity in children. J Pediatr 1991; 118: 531-534. Wan J, Corvino TF, Greenfield SP, et al. Kidney and testicle injuries in team and individual sports: Data from the national pediatric trauma registry. J Urol 2003; 170: 1528-1532. Ho PT, Zimmerman K, Wexler LH, et al. A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults. Cancer 1995; 76: 2557-2564. Paulino AC, Wen BC, Brown CK, et al. Late effects in children treated with radiation therapy for Wilms' tumor. Int J Radiat Oncol Biol Phys 2000; 46: 1239-1246. Bailey S, Roberts A, Brock C, et al. Nephrotoxicity in survivors of Wilms' tumours in the North of England. Br J Cancer 2002; 87: 1092-1098. Levitt GA, Yeomans E, Dicks Mireaux C, et al. Renal size and function after cure of Wilms' tumour. Br J Cancer 1992; 66: 877-882. Erdlenbruch B, Nier M, Kern W, et al. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients. Eur J Clin Pharmacol 2001; 57: 393-402. Srinivas M, Agarwala S, Padhy AK, et al. Somatic growth and renal function after unilateral nephrectomy for Wilms' tumor. Pediatr Surg Int 1998; 14: 185-188. Prasad VK, Lewis IJ, Aparicio SR, et al. Progressive glomerular toxicity of ifosfamide in children. Med Pediatr Oncol 1996; 27: 149-155. Loebstein R, Atanackovic G, Bishai R, et al. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. J Clin Pharmacol 1999; 39: 454-461. Welch TR, McAdams AJ. Focal glomerulosclerosis as a late sequela of Wilms tumor. J Pediatr 1986; 108: 105-109. Gerstenbluth RE, Spirnak JP, Elder JS. Sports participation and high grade renal injuries in children. J Urol 2002; 168: 2575-2578. Ariceta G, Rodriguez-Soriano J, Vallo A, et al. Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. Med Pediatr Oncol 1997; 28: 35-40. Hempel L, Misselwitz J, Fleck C, et al. Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function. Med Pediatr Oncol 2003; 40: 348-354. Cohen EP, Robbins ME. Radiation nephropathy. Semin Nephrol 2003; 23: 486-499. Egeler RM, Wolff JE, Anderson RA, et al. Long-term complications and post-treatment follow-up of patients with Wilms' tumor. Semin Urol Oncol 1999; 17: 55-61. Widemann BC, Balis FM, Kempf-Bielack B, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 2004; 100: 2222-2232. Gutierrez-Millet V, Nieto J, Praga M, et al. Focal glomerulosclerosis and proteinuria in patients with solitary kidneys. Arch Intern Med 1986; 146: 705-709. Berrak SG, Pearson M, Berberoglu S, et al. High-dose ifosfamide in relapsed pediatric osteosarcoma: Therapeutic effects and renal toxicity. Pediatr Blood Cancer 2005; 44: 215-219. Stohr W, Paulides M, Bielack S, et al. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: A report from the Late Effects Surveillance System. Pediatr Blood Cancer 2007; 48: 447-452. Raney B, Ensign LG, Foreman J, et al. Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor. Am J Pediatr Hematol Oncol 1994; 16: 286-295. Smith GR, Thomas PR, Ritchey M, et al. Long-term renal function in patients with irradiated bilateral Wilms tumor. National Wilms' Tumor Study Group. Am J Clin Oncol 1998; 21: 58-63. Skinner R, Cotterill SJ, Stevens MC. Risk factors for nephrotoxicity after ifosfamide treatment in children: A UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group. Br J Cancer 2000; 82: 1636-1645. Sharp DS, Ross JH, Kay R. Attitudes of pediatric urologists regarding sports participation by children with a solitary kidney. J Urol 2002; 168: 1811-1814; discussion 1815. Skinner R. Chronic ifosfamide nephrotoxicity in children. Med Pediatr Oncol 2003; 41: 190-197. Suarez A, McDowell H, Niaudet P, et al. Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: An International Society of Pediatric Oncology report. J Clin Oncol 1991; 9: 2177-2182. Townsend DM, Deng M, Zhang L, et al. Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 2003; 14: 1-10. Rossi R, Kleta R, Ehrich JH. Renal involvement in children with malignancies. Pediatr Nephrol 1999; 13: 153-162. Ginsberg JP, Hobbie WL, Ogle SK, et al. Prevalence of and risk factors for hydrocele in survivors of Wilms tumor. Pediatr Blood Cancer 2004; 42: 361-363. de Graaf SS, van Gent H, Reitsma-Bierens WC, et al. Renal function after unilateral nephrectomy for Wilms' tumour: The influence of radiation therapy. Eur J Cancer 1996; 32A: 465-469. Jones DP, Chesney RW. Renal toxicity of cancer chemotherapeutic agents in children: Ifosfamide and cisplatin. Curr Opin Pediatr 1995; 7: 208-213. Keaney CM, Springate JE. Cancer and the kidney. Adolesct Med Clin 2005; 121: 121-148. Mpofu C, Mann JR. Urinary protein/creatinine index in follow up of patients with Wilms' tumour after nephrectomy. Arch Dis Child 1992; 67: 1462-1466. American Academy of Pediatrics. Medical conditions affecting sports participation. Pediatrics 2001; 107: 1205-1209. Winn RJ, Botnick WZ. The NCCN Guideline Program: A conceptual framework. Oncology (Williston Park) 1997; 11: 25-32. Loebstein R, Koren G. Ifosfamide-induced nephrotoxicity in children: Critical review of predictive risk factors. Pediatrics 1998; 101: E8. Womer RB, Pritchard J, Barratt TM. Renal toxicity of cisplatin in children. J Pediatr 1985; 106: 659-663. Skinner R, Pearson AD, English MW, et al. Cisplatin dose rate as a risk factor for nephrotoxicity in children. Br J Cancer 1998; 77: 1677-1682. Fels LM, Bokemeyer C, van Rhee J, et al. Evaluation of late nephrotoxicity in long-term survivors of Hodgkin's disease. Oncology 1996; 53: 73-78. Arndt C, Morgenstern B, Hawkins D, et al. Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma. Med Pediatr Oncol 1999; 32: 93-96. Hartmann JT, Fels LM, Franzke A, et al. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/− ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide. Anticancer Res 2000; 20: 3767-3773. Ritchey ML, Green DM, Thomas PR, et al. Renal failure in Wilms' tumor patients: A report from the National Wilms' Tumor Study Group. Med Pediatr Oncol 1996; 26: 75-80. Rossi R, Pleyer J, Schafers P, et al. Development of ifosfamide-induced nephrotoxicity: Prospective follow-up in 75 patients. Med Pediatr Oncol 1999; 32: 177-182. Marina NM, Poquette CA, Cain AM, et al. Comparative renal tubular toxicity of chemotherapy regimens including ifosfamide in patients with newly diagnosed sarcomas. J Pediatr Hematol Oncol 2000; 22: 112-118. 2005; 174 1986; 75 2000; 46 1995; 76 2003; 14 1991; 118 2001; 107 1986; 108 1986; 146 1997; 11 1999; 17 2002; 87 1999; 13 1969; 44 1996; 27 2001; 57 2003; 40 2003; 41 1996; 26 1998; 14 2004; 100 1995; 9 2004; 42 1996; 32A 2000; 22 2000; 20 1997; 28 2003; 170 2004 1985; 106 2003 1998; 21 1991; 9 2005; 44 1996; 53 1995; 7 1990; 117 1993; 16 2005; 121 1999; 39 2002; 168 1999; 32 2000; 82 1994; 16 1992; 66 1998; 101 1992; 67 1998; 77 2007; 48 2003; 23 8393271 - Am J Clin Oncol. 1993 Jun;16(3):201-5 8580014 - Pediatr Nephrol. 1995 Oct;9(5):579-82 8814694 - Eur J Cancer. 1996 Mar;32A(3):465-9 16217371 - J Urol. 2005 Nov;174(5):1972-5 10073407 - Semin Urol Oncol. 1999 Feb;17(1):55-61 10064184 - Med Pediatr Oncol. 1999 Mar;32(3):177-82 8699991 - Med Pediatr Oncol. 1996 Sep;27(3):149-55 7978043 - Am J Pediatr Hematol Oncol. 1994 Nov;16(4):286-95 9635848 - Br J Cancer. 1998 May;77(10):1677-82 11268452 - Anticancer Res. 2000 Sep-Oct;20(5C):3767-73 12692801 - Med Pediatr Oncol. 2003 Jun;40(6):348-54 3963952 - Arch Intern Med. 1986 Apr;146(4):705-9 12352366 - J Urol. 2002 Oct;168(4 Pt 2):1811-4; discussion 1815 9880744 - Pediatr Surg Int. 1998 Dec;14(3):185-8 16628552 - Pediatr Blood Cancer. 2007 Apr;48(4):447-52 8570137 - Oncology. 1996 Jan-Feb;53(1):73-8 3003314 - J Pediatr. 1986 Jan;108(1):105-9 15503294 - Pediatr Blood Cancer. 2005 Mar;44(3):215-9 12868118 - Med Pediatr Oncol. 2003 Sep;41(3):190-7 11331710 - Pediatrics. 2001 May;107(5):1205-9 9430176 - Oncology (Williston Park). 1997 Nov;11(11A):25-32 12441987 - J Urol. 2002 Dec;168(6):2575-8 7787938 - Curr Opin Pediatr. 1995 Apr;7(2):208-13 12402147 - Br J Cancer. 2002 Nov 4;87(10):1092-8 4312366 - Pediatrics. 1969 Dec;44(6):912-21 11599657 - Eur J Clin Pharmacol. 2001 Aug;57(5):393-402 10779023 - J Pediatr Hematol Oncol. 2000 Mar-Apr;22(2):112-8 10234592 - J Clin Pharmacol. 1999 May;39(5):454-61 10725637 - Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1239-46 14966834 - Pediatr Blood Cancer. 2004 Apr;42(4):361-3 15844387 - Adolesc Med Clin. 2005 Feb;16(1):121-48 8950334 - Med Pediatr Oncol. 1997 Jan;28(1):35-40 12506132 - J Am Soc Nephrol. 2003 Jan;14(1):1-10 2984399 - J Pediatr. 1985 Apr;106(4):659-63 9606250 - Pediatrics. 1998 Jun;101(6):E8 8531856 - Med Pediatr Oncol. 1996 Feb;26(2):75-80 1329909 - Br J Cancer. 1992 Nov;66(5):877-82 1720453 - J Clin Oncol. 1991 Dec;9(12):2177-82 15139068 - Cancer. 2004 May 15;100(10):2222-32 1336953 - Arch Dis Child. 1992 Dec;67(12):1462-6 9950195 - Med Pediatr Oncol. 1999 Feb;32(2):93-6 8625085 - Cancer. 1995 Dec 15;76(12):2557-64 10817497 - Br J Cancer. 2000 May;82(10):1636-45 14501651 - J Urol. 2003 Oct;170(4 Pt 2):1525-7; discussion 1527 14501652 - J Urol. 2003 Oct;170(4 Pt 2):1528-3; discussion 1531-2 9499259 - Am J Clin Oncol. 1998 Feb;21(1):58-63 13680538 - Semin Nephrol. 2003 Sep;23(5):486-99 2166154 - J Pediatr. 1990 Aug;117(2 Pt 1):331-5 2007926 - J Pediatr. 1991 Apr;118(4 Pt 1):531-4 3014808 - Acta Paediatr Scand. 1986 May;75(3):408-14 10229006 - Pediatr Nephrol. 1999 Feb;13(2):153-62 Skinner R (e_1_2_5_20_2) 2000; 82 e_1_2_5_27_2 e_1_2_5_48_2 Raney B (e_1_2_5_10_2) 1994; 16 e_1_2_5_25_2 e_1_2_5_46_2 e_1_2_5_23_2 e_1_2_5_44_2 Brewer E (e_1_2_5_6_2) 2003 e_1_2_5_21_2 e_1_2_5_42_2 e_1_2_5_29_2 e_1_2_5_40_2 Hartmann JT (e_1_2_5_31_2) 2000; 20 e_1_2_5_13_2 e_1_2_5_9_2 e_1_2_5_15_2 e_1_2_5_36_2 e_1_2_5_7_2 e_1_2_5_34_2 e_1_2_5_55_2 e_1_2_5_11_2 e_1_2_5_32_2 e_1_2_5_53_2 e_1_2_5_17_2 e_1_2_5_19_2 e_1_2_5_30_2 e_1_2_5_51_2 e_1_2_5_26_2 e_1_2_5_49_2 Winn RJ (e_1_2_5_2_2) 1997; 11 e_1_2_5_24_2 e_1_2_5_47_2 e_1_2_5_22_2 e_1_2_5_45_2 e_1_2_5_43_2 Guignard J (e_1_2_5_3_2) 2003 e_1_2_5_28_2 e_1_2_5_41_2 Egeler RM (e_1_2_5_38_2) 1999; 17 e_1_2_5_14_2 e_1_2_5_37_2 e_1_2_5_16_2 e_1_2_5_35_2 e_1_2_5_8_2 e_1_2_5_33_2 e_1_2_5_56_2 e_1_2_5_12_2 e_1_2_5_54_2 e_1_2_5_18_2 e_1_2_5_39_2 Foreman JW (e_1_2_5_4_2) 2004 e_1_2_5_52_2 e_1_2_5_50_2 Flynn J (e_1_2_5_5_2) 2003 |
| References_xml | – start-page: 1180 year: 2003 end-page: 1197 – volume: 32 start-page: 177 year: 1999 end-page: 182 article-title: Development of ifosfamide‐induced nephrotoxicity: Prospective follow‐up in 75 patients publication-title: Med Pediatr Oncol – volume: 26 start-page: 75 year: 1996 end-page: 80 article-title: Renal failure in Wilms' tumor patients: A report from the National Wilms' Tumor Study Group publication-title: Med Pediatr Oncol – volume: 44 start-page: 912 year: 1969 end-page: 921 article-title: Long‐term follow‐up of renal functions of 108 children who underwent nephrectomy for malignant disease publication-title: Pediatrics – start-page: 399 year: 2003 end-page: 424 – volume: 28 start-page: 35 year: 1997 end-page: 40 article-title: Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis publication-title: Med Pediatr Oncol – volume: 117 start-page: 331 year: 1990 end-page: 335 article-title: Ifosfamide‐induced renal tubular dysfunction and rickets in children with Wilms tumor publication-title: J Pediatr – volume: 13 start-page: 153 year: 1999 end-page: 162 article-title: Renal involvement in children with malignancies publication-title: Pediatr Nephrol – volume: 170 start-page: 1525 year: 2003 end-page: 1527 article-title: The incidence of recreational genitourinary and abdominal injuries in the Western New York pediatric population publication-title: J Urol – volume: 20 start-page: 3767 year: 2000 end-page: 3773 article-title: Comparative study of the acute nephrotoxicity from standard dose cisplatin +/− ifosfamide and high‐dose chemotherapy with carboplatin and ifosfamide publication-title: Anticancer Res – volume: 76 start-page: 2557 year: 1995 end-page: 2564 article-title: A prospective evaluation of ifosfamide‐related nephrotoxicity in children and young adults publication-title: Cancer – volume: 101 start-page: E8 year: 1998 article-title: Ifosfamide‐induced nephrotoxicity in children: Critical review of predictive risk factors publication-title: Pediatrics – start-page: 1153 year: 2003 end-page: 1177 – volume: 67 start-page: 1462 year: 1992 end-page: 1466 article-title: Urinary protein/creatinine index in follow up of patients with Wilms' tumour after nephrectomy publication-title: Arch Dis Child – volume: 48 start-page: 447 year: 2007 end-page: 452 article-title: Ifosfamide‐induced nephrotoxicity in 593 sarcoma patients: A report from the Late Effects Surveillance System publication-title: Pediatr Blood Cancer – volume: 7 start-page: 208 year: 1995 end-page: 213 article-title: Renal toxicity of cancer chemotherapeutic agents in children: Ifosfamide and cisplatin publication-title: Curr Opin Pediatr – volume: 22 start-page: 112 year: 2000 end-page: 118 article-title: Comparative renal tubular toxicity of chemotherapy regimens including ifosfamide in patients with newly diagnosed sarcomas publication-title: J Pediatr Hematol Oncol – volume: 46 start-page: 1239 year: 2000 end-page: 1246 article-title: Late effects in children treated with radiation therapy for Wilms' tumor publication-title: Int J Radiat Oncol Biol Phys – volume: 107 start-page: 1205 year: 2001 end-page: 1209 article-title: Medical conditions affecting sports participation publication-title: Pediatrics – volume: 168 start-page: 1811 year: 2002 end-page: 1814 article-title: Attitudes of pediatric urologists regarding sports participation by children with a solitary kidney publication-title: J Urol – volume: 87 start-page: 1092 year: 2002 end-page: 1098 article-title: Nephrotoxicity in survivors of Wilms' tumours in the North of England publication-title: Br J Cancer – volume: 32 start-page: 93 year: 1999 end-page: 96 article-title: Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma publication-title: Med Pediatr Oncol – volume: 32A start-page: 465 year: 1996 end-page: 469 article-title: Renal function after unilateral nephrectomy for Wilms' tumour: The influence of radiation therapy publication-title: Eur J Cancer – volume: 39 start-page: 454 year: 1999 end-page: 461 article-title: Risk factors for long‐term outcome of ifosfamide‐induced nephrotoxicity in children publication-title: J Clin Pharmacol – volume: 9 start-page: 2177 year: 1991 end-page: 2182 article-title: Long‐term follow‐up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: An International Society of Pediatric Oncology report publication-title: J Clin Oncol – volume: 146 start-page: 705 year: 1986 end-page: 709 article-title: Focal glomerulosclerosis and proteinuria in patients with solitary kidneys publication-title: Arch Intern Med – volume: 11 start-page: 25 year: 1997 end-page: 32 article-title: The NCCN Guideline Program: A conceptual framework publication-title: Oncology (Williston Park) – volume: 44 start-page: 215 year: 2005 end-page: 219 article-title: High‐dose ifosfamide in relapsed pediatric osteosarcoma: Therapeutic effects and renal toxicity publication-title: Pediatr Blood Cancer – volume: 14 start-page: 1 year: 2003 end-page: 10 article-title: Metabolism of cisplatin to a nephrotoxin in proximal tubule cells publication-title: J Am Soc Nephrol – volume: 14 start-page: 185 year: 1998 end-page: 188 article-title: Somatic growth and renal function after unilateral nephrectomy for Wilms' tumor publication-title: Pediatr Surg Int – volume: 16 start-page: 201 year: 1993 end-page: 205 article-title: Diastolic hypertension in Wilms' tumor survivors: A late effect of treatment? A report from the National Wilms' Tumor Study Group publication-title: Am J Clin Oncol – volume: 27 start-page: 149 year: 1996 end-page: 155 article-title: Progressive glomerular toxicity of ifosfamide in children publication-title: Med Pediatr Oncol – volume: 100 start-page: 2222 year: 2004 end-page: 2232 article-title: High‐dose methotrexate‐induced nephrotoxicity in patients with osteosarcoma publication-title: Cancer – volume: 174 start-page: 1972 year: 2005 end-page: 1975 article-title: End stage renal disease in patients with Wilms tumor: Results from the National Wilms Tumor Study Group and the United States Renal Data System publication-title: J Urol – volume: 53 start-page: 73 year: 1996 end-page: 78 article-title: Evaluation of late nephrotoxicity in long‐term survivors of Hodgkin's disease publication-title: Oncology – volume: 121 start-page: 121 year: 2005 end-page: 148 article-title: Cancer and the kidney publication-title: Adolesct Med Clin – volume: 41 start-page: 190 year: 2003 end-page: 197 article-title: Chronic ifosfamide nephrotoxicity in children publication-title: Med Pediatr Oncol – volume: 21 start-page: 58 year: 1998 end-page: 63 article-title: Long‐term renal function in patients with irradiated bilateral Wilms tumor. National Wilms' Tumor Study Group publication-title: Am J Clin Oncol – volume: 17 start-page: 55 year: 1999 end-page: 61 article-title: Long‐term complications and post‐treatment follow‐up of patients with Wilms' tumor publication-title: Semin Urol Oncol – volume: 108 start-page: 105 year: 1986 end-page: 109 article-title: Focal glomerulosclerosis as a late sequela of Wilms tumor publication-title: J Pediatr – volume: 75 start-page: 408 year: 1986 end-page: 414 article-title: A comparative study of size and function of the remnant kidney in patients nephrectomized in childhood for Wilms' tumor and hydronephrosis publication-title: Acta Paediatr Scand – volume: 118 start-page: 531 year: 1991 end-page: 534 article-title: Partial reversibility of cisplatin nephrotoxicity in children publication-title: J Pediatr – volume: 9 start-page: 579 year: 1995 end-page: 582 article-title: Renal function following unilateral nephrectomy for neuroblastoma and Wilms' tumour publication-title: Pediatr Nephrol – volume: 16 start-page: 286 year: 1994 end-page: 295 article-title: Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor publication-title: Am J Pediatr Hematol Oncol – volume: 42 start-page: 361 year: 2004 end-page: 363 article-title: Prevalence of and risk factors for hydrocele in survivors of Wilms tumor publication-title: Pediatr Blood Cancer – volume: 57 start-page: 393 year: 2001 end-page: 402 article-title: Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients publication-title: Eur J Clin Pharmacol – volume: 23 start-page: 486 year: 2003 end-page: 499 article-title: Radiation nephropathy publication-title: Semin Nephrol – volume: 106 start-page: 659 year: 1985 end-page: 663 article-title: Renal toxicity of cisplatin in children publication-title: J Pediatr – volume: 170 start-page: 1528 year: 2003 end-page: 1532 article-title: Kidney and testicle injuries in team and individual sports: Data from the national pediatric trauma registry publication-title: J Urol – volume: 77 start-page: 1677 year: 1998 end-page: 1682 article-title: Cisplatin dose rate as a risk factor for nephrotoxicity in children publication-title: Br J Cancer – volume: 168 start-page: 2575 year: 2002 end-page: 2578 article-title: Sports participation and high grade renal injuries in children publication-title: J Urol – volume: 40 start-page: 348 year: 2003 end-page: 354 article-title: Influence of high‐dose methotrexate therapy (HD‐MTX) on glomerular and tubular kidney function publication-title: Med Pediatr Oncol – volume: 66 start-page: 877 year: 1992 end-page: 882 article-title: Renal size and function after cure of Wilms' tumour publication-title: Br J Cancer – start-page: 789 year: 2004 end-page: 806 – volume: 82 start-page: 1636 year: 2000 end-page: 1645 article-title: Risk factors for nephrotoxicity after ifosfamide treatment in children: A UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group publication-title: Br J Cancer – start-page: 1180 volume-title: Pediatric nephrology year: 2003 ident: e_1_2_5_6_2 contributor: fullname: Brewer E – ident: e_1_2_5_12_2 doi: 10.1159/000227539 – ident: e_1_2_5_49_2 doi: 10.1097/00000421-199306000-00003 – ident: e_1_2_5_39_2 doi: 10.1038/sj.bjc.6600608 – ident: e_1_2_5_30_2 doi: 10.1097/01.ASN.0000042803.28024.92 – ident: e_1_2_5_7_2 doi: 10.1097/00008480-199504000-00016 – ident: e_1_2_5_18_2 doi: 10.1002/pbc.20228 – start-page: 789 volume-title: Pediatric nephrology year: 2004 ident: e_1_2_5_4_2 contributor: fullname: Foreman JW – ident: e_1_2_5_32_2 doi: 10.1002/cncr.20255 – volume: 11 start-page: 25 year: 1997 ident: e_1_2_5_2_2 article-title: The NCCN Guideline Program: A conceptual framework publication-title: Oncology (Williston Park) contributor: fullname: Winn RJ – ident: e_1_2_5_23_2 doi: 10.1016/S0022-3476(05)80557-8 – ident: e_1_2_5_28_2 doi: 10.1002/(SICI)1096-911X(199701)28:1<35::AID-MPO7>3.0.CO;2-U – ident: e_1_2_5_56_2 doi: 10.1016/S0022-5347(05)64420-5 – start-page: 1153 volume-title: Pediatric nephrology year: 2003 ident: e_1_2_5_5_2 contributor: fullname: Flynn J – ident: e_1_2_5_51_2 doi: 10.1097/01.ju.0000176800.00994.3a – ident: e_1_2_5_40_2 doi: 10.1001/archinte.146.4.705 – ident: e_1_2_5_42_2 doi: 10.1542/peds.44.6.912 – ident: e_1_2_5_26_2 doi: 10.1038/bjc.1998.276 – ident: e_1_2_5_15_2 doi: 10.1177/009127009903900504 – ident: e_1_2_5_44_2 doi: 10.1007/s003830050482 – ident: e_1_2_5_11_2 doi: 10.1002/1097-0142(19951215)76:12<2557::AID-CNCR2820761223>3.0.CO;2-9 – ident: e_1_2_5_45_2 doi: 10.1007/BF00860940 – ident: e_1_2_5_54_2 doi: 10.1097/01.ju.0000084430.96658.05 – ident: e_1_2_5_55_2 doi: 10.1097/01.ju.0000083999.16060.ff – ident: e_1_2_5_37_2 doi: 10.1097/00000421-199802000-00013 – ident: e_1_2_5_35_2 doi: 10.1007/s004670050585 – ident: e_1_2_5_50_2 doi: 10.1002/pbc.10480 – ident: e_1_2_5_17_2 doi: 10.1002/mpo.10336 – ident: e_1_2_5_47_2 doi: 10.1111/j.1651-2227.1986.tb10222.x – ident: e_1_2_5_24_2 doi: 10.1016/S0022-3476(85)80098-6 – volume: 20 start-page: 3767 year: 2000 ident: e_1_2_5_31_2 article-title: Comparative study of the acute nephrotoxicity from standard dose cisplatin +/− ifosfamide and high‐dose chemotherapy with carboplatin and ifosfamide publication-title: Anticancer Res contributor: fullname: Hartmann JT – ident: e_1_2_5_43_2 doi: 10.1136/adc.67.12.1462 – ident: e_1_2_5_29_2 doi: 10.1542/peds.101.6.e8 – ident: e_1_2_5_27_2 doi: 10.1016/S0022-3476(05)83372-4 – ident: e_1_2_5_19_2 doi: 10.1002/pbc.20858 – ident: e_1_2_5_33_2 doi: 10.1002/mpo.10293 – ident: e_1_2_5_16_2 doi: 10.1016/S0360-3016(99)00534-9 – ident: e_1_2_5_53_2 doi: 10.1016/S0022-5347(05)64219-X – ident: e_1_2_5_36_2 doi: 10.1002/(SICI)1096-911X(199602)26:2<75::AID-MPO1>3.0.CO;2-R – ident: e_1_2_5_14_2 doi: 10.1002/(SICI)1096-911X(199903)32:3<177::AID-MPO3>3.0.CO;2-H – volume: 82 start-page: 1636 year: 2000 ident: e_1_2_5_20_2 article-title: Risk factors for nephrotoxicity after ifosfamide treatment in children: A UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group publication-title: Br J Cancer contributor: fullname: Skinner R – ident: e_1_2_5_46_2 doi: 10.1016/0959-8049(95)00618-4 – ident: e_1_2_5_21_2 doi: 10.1097/00043426-200003000-00007 – volume: 16 start-page: 286 year: 1994 ident: e_1_2_5_10_2 article-title: Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor publication-title: Am J Pediatr Hematol Oncol contributor: fullname: Raney B – ident: e_1_2_5_41_2 doi: 10.1016/S0022-3476(86)80781-8 – ident: e_1_2_5_9_2 doi: 10.1200/JCO.1991.9.12.2177 – ident: e_1_2_5_34_2 doi: 10.1016/S0270-9295(03)00093-7 – start-page: 399 volume-title: Pediatric nephrology year: 2003 ident: e_1_2_5_3_2 contributor: fullname: Guignard J – ident: e_1_2_5_25_2 doi: 10.1007/s002280100319 – volume: 17 start-page: 55 year: 1999 ident: e_1_2_5_38_2 article-title: Long‐term complications and post‐treatment follow‐up of patients with Wilms' tumor publication-title: Semin Urol Oncol contributor: fullname: Egeler RM – ident: e_1_2_5_22_2 doi: 10.1002/(SICI)1096-911X(199902)32:2<93::AID-MPO4>3.0.CO;2-Y – ident: e_1_2_5_52_2 doi: 10.1542/peds.107.5.1205 – ident: e_1_2_5_48_2 doi: 10.1038/bjc.1992.378 – ident: e_1_2_5_13_2 doi: 10.1002/(SICI)1096-911X(199609)27:3<149::AID-MPO3>3.0.CO;2-E – ident: e_1_2_5_8_2 doi: 10.1016/j.admecli.2004.09.012 |
| SSID | ssj0026058 |
| Score | 2.292881 |
| SecondaryResourceType | review_article |
| Snippet | Improvements in childhood cancer therapy have led to increasing numbers of long‐term survivors. These survivors are at risk for a variety of late effects due... Improvements in childhood cancer therapy have led to increasing numbers of long-term survivors. These survivors are at risk for a variety of late effects due... |
| SourceID | pubmedcentral crossref pubmed wiley istex |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 724 |
| SubjectTerms | Antineoplastic Agents - adverse effects Child chronic kidney disease cisplatin Humans hypertension ifosfamide Kidney - drug effects Kidney - radiation effects Kidney Diseases - etiology methotrexate Neoplasms - therapy nephrectomy proteinuria radiotherapy Radiotherapy - adverse effects Wilms' tumor |
| Title | Renal late effects in patients treated for cancer in childhood: A report from the Children's Oncology Group |
| URI | https://api.istex.fr/ark:/67375/WNG-WWRD9HFW-N/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fpbc.21695 https://www.ncbi.nlm.nih.gov/pubmed/18677764 https://pubmed.ncbi.nlm.nih.gov/PMC2734519 |
| Volume | 51 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ1ZS8QwEMcHXUF88T7qRRBRX6ptekafdHXdF1fxYH0rbZqgKFV2XdBv70zara4gCL4VkpaQyfGfZOZXgG0R4cqrlGerWIa2r7S0U55mdiwdFKeh9kKXcofbN1HnPj49I0zO0TAXpuRD1AduNDPMek0TPM36B1_Q0NdM7nM3FJRgjl6CSd_wrmpni677DCvVD-wAhcSQKuTwg_rNkb1ogrr1_dtG9DNI8rt4NbtPa-Zf7Z6F6Up0suNylMzBmCrmYfKiulZfgKdrReXPqDtZFeDBHgtWMVf7zESjq5yhwGWShkmPiuWQinzIjll598AoW4WhpmTNKkl8t88uC0PG_mDmnGsR7lpnt822Xf2FwZYBaguba-WKPPZV5IWeiwMv00LkIvZFHEjfQ_8w10JzAhuih6uk4JFWXDmxUI5GZ8xbgkbxUqgVYDrlmUxxReMRemGUZa49hb65FrEj3UBbsDW0R_JawjaSEqvME-y2xHSbBTvGUnWNtPdE0WlRkHQ750m3e30q2q1u0rFgubTg17cI3heFvgXRiG3rCsTaHi0pHh8Mc5soQCh2Ldgztv29ecnVSdM8rP696hpMmTAUEyWzDo233kBtwHg_H2yaQf0J8J75Tg |
| link.rule.ids | 230,315,782,786,887,1408,27933,27934,46064,46488 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ3bS-QwFIcPXkD3xbtuvaxBRH2ptuk14ouOzs6ijuKF8S100oQVlyozCvrfe07aqc6CsLBvhaSl5Jwmv5Oc8xVgUyQ482oduDpVsRtqo9yMZ103VR6K09gEsU-1w63rpH2XHp8QJudgUAtT8iHqDTf6Mux8TR84bUjvfVBDn7pql_uxiEZhPIzREamAI7iswy068LO01DByI5QSA66Qx_fqW4dWo3Ea2NdPS9HfaZKf5atdf5rT__fmMzBV6U52WDrKLIzoYg4mzquT9Xl4uNLU_gelJ6tyPNh9wSrsap_ZhHSdM9S4TJGn9KhZDcDI--yQlccPjApWGMpK1qjqxLf77KKwcOw3Zre6FuC2eXLTaLnVjxhcFaG8cLnRvsjTUCdBHPjoe10jRC7SUKSRCgMMEXMjDCe2IQa5WgmeGM21lwrtGYzHgkUYKx4L_R2YyXhXZTip8QQDMSo0N4HG8NyI1FN-ZBzYGBhEPpW8DVmSlbnEYZN22BzYsqaqe2S9B0pQSyLZaf-Unc7VsWg1O7LtwFJpwo9nEb8viUMHkiHj1h0Itz3cUtz_tthtAgGh3nVgxxr369eTl0cNe7H8713XYbJ1c34mz361T1fgm81KsUkzqzD23HvRazDaz19-WA9_B6rP_XY |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ3ZT9wwEIdHHBLqC0cPCFctVLV9SUnsXIYn2GXZqu12RVstb1bWsQUChdUuSPDfM-NkA1sJqVLfItmJLI-P39gzXwA-yBRXXmOEbzKd-JGx2s95PvQzHaA4TaxIQsod7v5Ke-dZ-4QwOYfTXJiKD9EcuNHMcOs1TfBRYfefoKGjof7Cw0TG87AYoQwncL4Q_cbbovs-B0uNYj9GJTHFCgV8v3l1ZjNapH69f7YT_R0l-Vy9uu2ns_JfDV-F5Vp1sqNqmKzBnClfw9KP-l79DVydGSq_RuHJ6ggPdlmyGro6YS4c3RQMFS7TNE7GVKynWOQDdsSqywdG6SoMRSVr1VninybsZ-nQ2A_MHXS9hT-dk9-trl__hsHXMYoLn1sTyiKLTCoSEeLIG1opC5lFMot1JNBBLKy0nMiG6OIaLXlqDTdBJk1g0RsT72ChvCnNBjCb86HOcUnjKbphlGZuhUHn3Mos0GFsPdib2kONKtqGqrjKXGG3KddtHnx0lmpq5OMrCk9LYzXonarB4Kwtu52B6nmwXlnw6VtE70uTyIN0xrZNBYJtz5aUlxcOuk0YIFS7Hnx2tn25eap_3HIPm_9e9T0s9dsd9f1r79sWvHIhKS5iZhsWbsd3ZgfmJ8Xdrhvfj5ts_Bw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Renal+late+effects+in+patients+treated+for+cancer+in+childhood%3A+A+report+from+the+Children%27s+Oncology+Group&rft.jtitle=Pediatric+blood+%26+cancer&rft.au=Jones%2C+Deborah+P.&rft.au=Spunt%2C+Sheri+L.&rft.au=Green%2C+Daniel&rft.au=Springate%2C+James+E.&rft.date=2008-12-01&rft.pub=Wiley+Subscription+Services%2C+Inc.%2C+A+Wiley+Company&rft.issn=1545-5009&rft.eissn=1545-5017&rft.volume=51&rft.issue=6&rft.spage=724&rft.epage=731&rft_id=info:doi/10.1002%2Fpbc.21695&rft.externalDBID=10.1002%252Fpbc.21695&rft.externalDocID=PBC21695 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1545-5009&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1545-5009&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1545-5009&client=summon |